Microbial-based immunotherapy platform
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
10
NCT06336148
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 5, 2024
Completion: Aug 28, 2025
Loading map...